COMMUNIQUÉS West-GlobeNewswire

Five Prime Announces Pricing of Upsized Public Offering of Common Stock
25/01/2018
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq: FPRX ), announced today the pricing of an underwritten public offering of 5,128,205 shares of its common stock at a [...]
Achaogen Announces New Employment Inducement Grants
25/01/2018
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO ), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram- [...]
Interpace Diagnostics to Present at NobleCon14 on January 29
25/01/2018
PARSIPPANY, N.J. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- INTERPACE DIAGNOSTICS GROUP, INC.(NASDAQ: IDXG ), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests [...]
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
25/01/2018
SAN CARLOS, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA ), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) [...]
ProMIS Neurosciences Issues White Paper Entitled: “Not All Amyloid Beta Therapeutics Are Created Equal”
25/01/2018
ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Improved Therapeutic Potency versus other Amyloid Beta-Directed Antibodies ………….. … TORONTO and CAMBRIDGE, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE [...]
Provant Health to Present at the NobleCon14 on January 30, 2018
25/01/2018
OLATHE, Kan., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Hooper Holmes, Inc. d/b/a Provant Health (OTCQX:HPHW), the largest publicly-traded, pure-play well-being leader in workplace population health and clinical research [...]
DLT Resolution to acquire 80% of fast growing Canadian start-up A.J.D. Data Services Ltd.
25/01/2018
Las Vegas, NV, Jan. 25, 2018 (GLOBE NEWSWIRE) -- DLT Resolution Inc. (OTC: DLTI), a blockchain technology and data services company providing distributed ledger technology that currently services the healthcare and [...]
BGI Increases Long-Read Sequencing Capacity with Purchase of 10 PacBio Sequel Systems
25/01/2018
MENLO PARK, California and SHENZHEN, China, Jan. 25, 2018 (GLOBE NEWSWIRE) -- BGI, one of the world’s largest genomics organizations, and Pacific Biosciences of California, Inc. (Nasdaq: PACB), the leader in long-read [...]
Meridian Bioscience Reports First Quarter 2018 Operating Results, Declares Regular First Quarter Cash Dividend, and Reaffirms Fiscal 2018 Guidance
25/01/2018
CINCINNATI, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ) today: GENERAL HIGHLIGHTS reported first quarter net revenues of $52.3 million, an increase of 12% from the same period of the [...]
Summit Therapeutics plc : Interim 24-Week Data from PhaseOut DMD
25/01/2018
Summit Therapeutics plc ('Summit', or 'the Company') EZUTROMID SIGNIFICANTLY REDUCED MUSCLE DAMAGE IN DMD PATIENTS IN 24-WEEK INTERIM DATA FROM SUMMIT'S PhaseOut DMD CLINICAL TRIAL Increase in Utrophin Protein [...]
Sonoma Pharmaceuticals Announces Fiscal Third Quarter 2018 Financial Results and Conference Call
25/01/2018
PETALUMA, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW) today announced that financial results for its fiscal third quarter 2018, ended December 31, 2017, will be [...]
Myriad to Announce Fiscal Second-Quarter 2018 Financial Results on February 6, 2018
25/01/2018
SALT LAKE CITY, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN ) today announced that it will hold its fiscal second-quarter 2018 sales and earnings conference call with investors and analysts at [...]
Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial
25/01/2018
Increase in Utrophin Protein Expression Observed Summit Accelerating Preparations for Pivotal Clinical Trial Ezutromid is a Potential Disease-Modifying Treatment for the Entire DMD Patient Population Conference Call [...]
NeuroMetrix Reports Q4 and Full Year 2017 Financial Results
25/01/2018
WALTHAM, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO ), today reported financial and business highlights for the quarter ended December 31, 2017. The Company develops and markets novel [...]
Athenex, Inc. Announces Pricing of Offering of Common Stock
25/01/2018
BUFFALO, N.Y., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer [...]
Eyenovia Announces Pricing of Initial Public Offering
25/01/2018
NEW YORK, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver [...]
Menlo Therapeutics Inc. Announces Pricing of Initial Public Offering of Common Stock
25/01/2018
REDWOOD CITY, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO ) today announced the pricing of the Company’s initial public offering of 7,000,000 shares of common stock at a public [...]
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Landmark Epidiolex® (cannabidiol) Study in The Lancet
25/01/2018
– First well-controlled clinical study of cannabidiol in Lennox-Gastaut syndrome, a rare, severe, form of childhood-onset epilepsy that is difficult to treat – – Pharmaceutical formulation of cannabidiol significantly [...]
REVA Announces First Implant of the Fantom Bioresorbable Scaffold in Italy
24/01/2018
SAN DIEGO, Jan. 24, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the first implant of the Fantom [...]

Pages